Welcome!

News Feed Item

/C O R R E C T I O N -- MitoQ Limited/

In the news release, Antioxidant Shows Promise in Supporting Treatment for Lou Gehrig's Disease, issued 24-Mar-2014 over PR Newswire, we are advised by the company that the source being attributed should be "The Center of Free Radical and Biomedical Research" rather than "MitoQ Limited"; and the headline should read "Antioxidant Shows Promise in Fight Against Lou Gehrig's Disease" rather than "Antioxidant Shows Promise in Supporting Treatment for Lou Gehrig's Disease" as originally issued inadvertently. The complete, corrected release follows:

Antioxidant Shows Promise in Fight Against Lou Gehrig's Disease

MONTEVIDEO, Uruguay, March 24, 2014 /PRNewswire/ -- Researchers at The Center of Free Radical and Biomedical Research at Facultad de Medicina, Universidad de la Republica in Uruguay today announced the discovery that the antioxidant MitoQ prolonged the lifespan and health-span of mice suffering from amyotrophic lateral sclerosis-like (ALS) disease, and successfully improved functional parameters related to muscular strength and reversed mitochondrial damage in nervous and muscle tissue. The study was published in the journal Free Radical Biology and Medicine and the findings of this study point to a positive direction for those suffering from ALS.

Rafael Radi, MD, PhD, headed a research study that found MitoQ was able to extend the lifespan of mice with ALS.

MitoQ is a mitochondria-targeted antioxidant created over a decade ago that reduces mitochondrial oxidative stress and, when administered to a mouse model of ALS, delayed the progression of the fatal neurodegenerative disease. Mitochondria are also known as cellular batteries and provide energy to cells.  

Commonly known as Lou Gehrig's or Motor Neuron disease, ALS is a disorder within the nerve cells of the brain and spinal cord that control voluntary muscle movement, and ultimately results in progressive paralysis and death. The results of this study show a promise that mitochondria-targeted antioxidants could potentially be of use for the treatment of ALS, a condition for which there is currently no cure.

"This study supports the role of mitochondrial dysfunction in the development and progression of ALS, which may allow for the development of more mitochondria-targeted therapies to fight this disease," said Rafael Radi, MD, PhD, Director of the Center and a key member of the study's research team. "We also found that MitoQ has beneficial effects in the murine model of ALS, which will likely lead to clinical trials using MitoQ with ALS patients and hopefully lead to extend the survival and improve the quality of life of ALS patients."

Researchers sought to decrease oxidative stress in mitochondria as a way to slow the death of motor neurons and disease progression within the ALS-induced mice. MitoQ works by accumulating inside the mitochondria and performing antioxidant activity, while allowing the molecule to act specifically at the site of free radical formation in the cells and efficiently reduce oxidative stress.

To conduct their study, scientists administered MitoQ to the mice's drinking water from a time when early symptoms of neurodegeneration had become evident. After 20 days of administration, MitoQ was detected in all tested tissues and the treatment had slowed the decline of mitochondrial function in both the spinal cord and the quadriceps muscles.

"MitoQ increased approximately 6% the survival of the treated mice," noted Patricia Cassina, MD, PhD, another key senior member of the research team. "This might seem small, but it's in the range of the best that other drugs have been able to achieve with this model in which the disease progression is extremely fast and there is a small window of opportunity to improve symptoms and survival." Radi noted that MitoQ administration also resulted in improved muscular strength as evaluated by functional tests performed in the animals.

An advantage of MitoQ is that it has been tested for safety in a variety of clinical human trials since its inception in the late 1990s. The Center of Free Radical and Biomedical Research is now evaluating the possibility of conducting clinical human trials specifically related to MitoQ and its effects on ALS patients.

Photo - http://photos.prnewswire.com/prnh/20140324/NY88535

SOURCE The Center of Free Radical and Biomedical Research

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing be...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Analytic. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.